Rather than committing exclusively to monotherapy or adjunctive indications, Draig launched two concurrent Phase 2 studies. A global monotherapy study isolates DT101's dose response without confounding background therapies, confirming biological activity. Simultaneously, a US adjunctive study tests the asset on top of standard antidepressants, matching the commercial standard of care where patients failing frontline generic SSRIs or SNRIs require background combination regimens.
Psychiatric clinical trials often fail due to poorly managed placebo responses and subjective rating endpoints. Inder Kaul argues that rushing enrollment undermines patient quality. Beyond ticking box-checking eligibility criteria, teams must ensure candidates meet the protocol's clinical intent. Additionally, controlling placebo response demands minimizing unnecessary patient burden, selecting sites carefully, and enforcing strict intra- and inter-rater calibration across trial sites.
Standard regulatory frameworks recognize fast antidepressant onset within seven days. However, Draig purposefully engineered DT101 with a pulsatile pharmacokinetic profile that allows transient AMPA receptor engagement. Inder Kaul notes this design mechanistically aligns with the synaptic plasticity biology demonstrated by esketamine and psychedelics, aiming to separate from placebo and drive robust, durable antidepressant efficacy as early as day four.
Psychiatry drug development routinely suffers from an absence of functional pharmacodynamic biomarkers. Draig addressed this in Phase 1 by implementing magnetoencephalography (MEG) within single- and repeat-dose crossover trial designs. Measuring direct functional brain responses across dose levels within participants boosted assay sensitivity and generated objective pharmacodynamic evidence, which directly informed dose selection for subsequent Phase 2 trials.
